Lupin releases Q4FY22 results
Basis the long-term outlook, the company's Board has recommended a dividend of 200 per cent
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
financial highlights
Morepen Labs’s annual FY22 revenue increases by 30 per cent
Consolidated Profit Before Tax (PBT) at Rs 126.70 crores has risen by 29 per cent in FY22 and Profit After Tax (PAT) at Rs 101.68…
Lincoln Pharma reports 30.50 per cent rise in standalone net profit at Rs 17.60 crores in Q3 FY22
The company reported an EBITDA of Rs 26.09 crores in Q3FY22, a rise of 25.90 per cent as compared to Rs 20.72 crores in the…
Dishman Carbogen Amcis records 16.1 per cent growth YoY in consolidated net sales
Total Expenses amounted to Rs 537.17 crores, up two per cent QoQ
Lincoln Pharmaceuticals reports 28.33 per cent rise in standalone net profit in Q4 FY21
Company recommends dividend of 15 per cent – Rs 1.5 per share for FY21